Blue Horizon International team to attend Clinical Trials Masterclass in New York

Press Release (ePRNews.com) - NEW YORK - Feb 13, 2017 - Brian Mehling, M.D. and Marina Manvelyan, Ph.D., will attend a three-day long Masterclass in Clinical Trials and Medicine Development from February 22 – 24, 2017 in New York, NY.

The Masterclass in Clinical Trials is designed to provide insight into new business opportunities in the field of clinical trials and the development process of new healthcare interventions. The course will provide insight into complex cross-disciplinary integrated health within the process of diffusion of new medical interventions, from pharmaceuticals, medical devices, diagnostics, surgical interventions to dietary supplements.

Dr. Mehling will attend the course with Marina Manvelyan, PhD., Blue Horizon International’s clinical research scientist.

Dr Mehling said, “I am looking forward to the lectures and practical sessions that will cover the key issues to be considered in design, conduct, analysis and reporting, with a focus on major clinical trials which directly influence clinical practice.”

The course will be led by Carl Naraynassamy. His clinical research career includes work for Aventis, Kendle Inc and GlaxoWellcome. His professional association work includes the Association of Clinical Research Professionals & the Academy of Pharmaceutical Physicians and Investigators. His academic work includes Hibernia College, Dublin and The London School of Tropical Medicine, London University.

The participants will discover new approaches in drug developing technologies and clinical trial management.

BHI Therapeutic Sciences, LLC currently offers cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital in Slovakia and is fully licensed by the Ministry of Health of the Slovak Republic. For more information, please visit www.bhisciences.com.

Source : Blue Horizon International

You may also like this  

CATEGORIES : Healthcare Medical
DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login